1. Pro Re Nata Intravitreal Bevacizumab for the Treatment of Idiopathic Choroidal Neovascular Membrane.
- Author
-
Saurabh K, Roy R, Panigrahi PK, Lobo A, and Majumdar AK
- Subjects
- Adolescent, Adult, Choroidal Neovascularization diagnosis, Choroidal Neovascularization physiopathology, Female, Fluorescein Angiography, Humans, Intravitreal Injections, Male, Middle Aged, Retreatment, Retrospective Studies, Tomography, Optical Coherence, Vascular Endothelial Growth Factor A antagonists & inhibitors, Visual Acuity physiology, Angiogenesis Inhibitors therapeutic use, Bevacizumab therapeutic use, Choroidal Neovascularization drug therapy
- Abstract
Purpose: To study the efficacy of intravitreal bevacizumab on a pro re nata basis for treatment of idiopathic choroidal neovascular membrane., Material and Methods: Thirty-seven eyes of 37 patients presenting with idiopathic choroidal neovascular membrane were included in the study. Intravitreal bevacizumab (1.25 mg/0.05 ml) was given on a pro re nata basis from the base line., Results: Twenty-one (58.3%) patients were male and 15 (41.7%) were female aged 13-49 years. Idiopathic choroidal neovascular membrane showed a classic leak on fluorescein angiogram in all the eyes. Subfoveal location (25; 67.6%) was the commonest site of involvement. Mean number of intravitreal bevacizumab injections required to achieve resolution was 2.81 ± 1.4. At final follow-up, 31 (83.8%) eyes had maintained or improved vision (Group A) and six (16.2%) eyes had worsening of vision (Group B). There was no significant difference in mean age, gender, and mean number of injections between groups A and B., Conclusion: Intravitreal bevacizumab on a pro re nata basis is effective in the treatment of idiopathic choroidal neovascular membrane. A larger controlled study would be required to formulate an accurate injection protocol.
- Published
- 2016
- Full Text
- View/download PDF